Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Stephanie Mullan"'
Autor:
Tyler L. Bissoondial, Yiguang Han, Stephanie Mullan, Amrit K. Pabla, Kiera Spahn, Steven Shi, Lana Zheng, Ping Zhou, Kai Jiang, Natalia Prakash, Shraddha Bhutkar, Quaisar Ali, Jingsong Li, Zhijian Hu, Anthony J. Pellicano, Itzhak D. Goldberg, Prakash Narayan
Publikováno v:
Diagnostics, Vol 10, Iss 10, p 784 (2020)
There is increasing evidence that nonalcoholic steatohepatitis (NASH) is a risk factor for hepatocellular carcinoma (HCC) in the absence of cirrhosis, a phenomenon termed noncirrhotic HCC. Early diagnosis of HCC is critical to a favorable prognosis.
Externí odkaz:
https://doaj.org/article/135af65593844de493e4173d5d75c0ff
Publikováno v:
Processes
Volume 9
Issue 9
Processes, Vol 9, Iss 1516, p 1516 (2021)
Volume 9
Issue 9
Processes, Vol 9, Iss 1516, p 1516 (2021)
Non-alcoholic steatohepatitis (NASH) is associated with an increased risk of hepatocellular carcinoma (HCC). Expression levels of hepatic oncogenes, alpha-fetoprotein (afp) and osteopontin (opn)/secreted phosphoprotein 1 (spp1), were investigated usi
Autor:
Joaquim Bellmunt, Shamini Selvarajah, Scott Rodig, Marta Salido, Silvia de Muga, Irmgard Costa, Beatriz Bellosillo, Lillian Werner, Stephanie Mullane, André P Fay, Robert O'Brien, Jordi Barretina, André E Minoche, Sabina Signoretti, Clara Montagut, Heinz Himmelbauer, David M Berman, Philip Kantoff, Toni K Choueiri, Jonathan E Rosenberg
Publikováno v:
PLoS ONE, Vol 9, Iss 8, p e103325 (2014)
BACKGROUND: Anaplastic lymphoma kinase (ALK) genomic alterations have emerged as a potent predictor of benefit from treatment with ALK inhibitors in several cancers. Currently, there is no information about ALK gene alterations in urothelial carcinom
Externí odkaz:
https://doaj.org/article/bbf5118d3ed9435c9fbb95822615c00c